{"openapi":"3.1.0","info":{"title":"OmniRx static API","version":"1.0.0-evaluation","description":"Dated, provenance-stamped US drug-access facts (availability, price, assistance programs) pre-rendered from a frozen edition. Not clinical advice. Static files: no key, no rate limit, no uptime promise. Every answer lists the facts it rests on (receipts) and what it cannot say (unknown). Verify an edition root at https://omnirx.org/editions.json.","license":{"name":"See https://omnirx.org/license"}},"servers":[{"url":"https://omnirx.org"}],"paths":{"/api/v1/drugs/ozempic.json":{"get":{"summary":"Facts for ozempic: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)","operationId":"api_v1_drugs_ozempic_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/drugs/eliquis.json":{"get":{"summary":"Facts for eliquis: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)","operationId":"api_v1_drugs_eliquis_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/drugs/farxiga.json":{"get":{"summary":"Facts for farxiga: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)","operationId":"api_v1_drugs_farxiga_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/drugs/jardiance.json":{"get":{"summary":"Facts for jardiance: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)","operationId":"api_v1_drugs_jardiance_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/drugs/entresto.json":{"get":{"summary":"Facts for entresto: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)","operationId":"api_v1_drugs_entresto_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/drugs/trulicity.json":{"get":{"summary":"Facts for trulicity: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)","operationId":"api_v1_drugs_trulicity_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/drugs/cosentyx.json":{"get":{"summary":"Facts for cosentyx: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)","operationId":"api_v1_drugs_cosentyx_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/drugs/janumet.json":{"get":{"summary":"Facts for janumet: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)","operationId":"api_v1_drugs_janumet_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/drugs/biktarvy.json":{"get":{"summary":"Facts for biktarvy: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)","operationId":"api_v1_drugs_biktarvy_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/drugs/xarelto.json":{"get":{"summary":"Facts for xarelto: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)","operationId":"api_v1_drugs_xarelto_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/drugs/enbrel.json":{"get":{"summary":"Facts for enbrel: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)","operationId":"api_v1_drugs_enbrel_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/drugs/trelegy-ellipta.json":{"get":{"summary":"Facts for trelegy ellipta: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)","operationId":"api_v1_drugs_trelegy_ellipta_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/drugs/anoro-ellipta.json":{"get":{"summary":"Facts for anoro ellipta: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)","operationId":"api_v1_drugs_anoro_ellipta_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/drugs/austedo.json":{"get":{"summary":"Facts for austedo: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)","operationId":"api_v1_drugs_austedo_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/drugs/breo-ellipta.json":{"get":{"summary":"Facts for breo ellipta: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)","operationId":"api_v1_drugs_breo_ellipta_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/drugs/calquence.json":{"get":{"summary":"Facts for calquence: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)","operationId":"api_v1_drugs_calquence_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/drugs/cimzia.json":{"get":{"summary":"Facts for cimzia: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)","operationId":"api_v1_drugs_cimzia_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/drugs/entyvio.json":{"get":{"summary":"Facts for entyvio: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)","operationId":"api_v1_drugs_entyvio_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/drugs/erleada.json":{"get":{"summary":"Facts for erleada: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)","operationId":"api_v1_drugs_erleada_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/drugs/ibrance.json":{"get":{"summary":"Facts for ibrance: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)","operationId":"api_v1_drugs_ibrance_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/drugs/imbruvica.json":{"get":{"summary":"Facts for imbruvica: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)","operationId":"api_v1_drugs_imbruvica_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/drugs/januvia.json":{"get":{"summary":"Facts for januvia: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)","operationId":"api_v1_drugs_januvia_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/drugs/kisqali.json":{"get":{"summary":"Facts for kisqali: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)","operationId":"api_v1_drugs_kisqali_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/drugs/lenvima.json":{"get":{"summary":"Facts for lenvima: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)","operationId":"api_v1_drugs_lenvima_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/drugs/linzess.json":{"get":{"summary":"Facts for linzess: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)","operationId":"api_v1_drugs_linzess_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/drugs/novolog.json":{"get":{"summary":"Facts for novolog: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)","operationId":"api_v1_drugs_novolog_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/drugs/ofev.json":{"get":{"summary":"Facts for ofev: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)","operationId":"api_v1_drugs_ofev_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/drugs/orencia.json":{"get":{"summary":"Facts for orencia: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)","operationId":"api_v1_drugs_orencia_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/drugs/otezla.json":{"get":{"summary":"Facts for otezla: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)","operationId":"api_v1_drugs_otezla_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/drugs/pomalyst.json":{"get":{"summary":"Facts for pomalyst: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)","operationId":"api_v1_drugs_pomalyst_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/drugs/rexulti.json":{"get":{"summary":"Facts for rexulti: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)","operationId":"api_v1_drugs_rexulti_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/drugs/stelara.json":{"get":{"summary":"Facts for stelara: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)","operationId":"api_v1_drugs_stelara_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/drugs/tradjenta.json":{"get":{"summary":"Facts for tradjenta: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)","operationId":"api_v1_drugs_tradjenta_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/drugs/verzenio.json":{"get":{"summary":"Facts for verzenio: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)","operationId":"api_v1_drugs_verzenio_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/drugs/vraylar.json":{"get":{"summary":"Facts for vraylar: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)","operationId":"api_v1_drugs_vraylar_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/drugs/xeljanz.json":{"get":{"summary":"Facts for xeljanz: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)","operationId":"api_v1_drugs_xeljanz_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/drugs/xifaxan.json":{"get":{"summary":"Facts for xifaxan: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)","operationId":"api_v1_drugs_xifaxan_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/drugs/xolair.json":{"get":{"summary":"Facts for xolair: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)","operationId":"api_v1_drugs_xolair_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/drugs/xtandi.json":{"get":{"summary":"Facts for xtandi: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)","operationId":"api_v1_drugs_xtandi_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/offers/ozempic.json":{"get":{"summary":"Manufacturer offers recorded for ozempic: savings card, self-pay price, free trial, with conditions and stated end dates (find_offers envelope)","operationId":"api_v1_offers_ozempic_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/offers/eliquis.json":{"get":{"summary":"Manufacturer offers recorded for eliquis: savings card, self-pay price, free trial, with conditions and stated end dates (find_offers envelope)","operationId":"api_v1_offers_eliquis_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/offers/cosentyx.json":{"get":{"summary":"Manufacturer offers recorded for cosentyx: savings card, self-pay price, free trial, with conditions and stated end dates (find_offers envelope)","operationId":"api_v1_offers_cosentyx_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/offers/biktarvy.json":{"get":{"summary":"Manufacturer offers recorded for biktarvy: savings card, self-pay price, free trial, with conditions and stated end dates (find_offers envelope)","operationId":"api_v1_offers_biktarvy_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/offers/xarelto.json":{"get":{"summary":"Manufacturer offers recorded for xarelto: savings card, self-pay price, free trial, with conditions and stated end dates (find_offers envelope)","operationId":"api_v1_offers_xarelto_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/offers/linzess.json":{"get":{"summary":"Manufacturer offers recorded for linzess: savings card, self-pay price, free trial, with conditions and stated end dates (find_offers envelope)","operationId":"api_v1_offers_linzess_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/offers/stelara.json":{"get":{"summary":"Manufacturer offers recorded for stelara: savings card, self-pay price, free trial, with conditions and stated end dates (find_offers envelope)","operationId":"api_v1_offers_stelara_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/offers/wegovy.json":{"get":{"summary":"Manufacturer offers recorded for wegovy: savings card, self-pay price, free trial, with conditions and stated end dates (find_offers envelope)","operationId":"api_v1_offers_wegovy_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/ozempic.json":{"get":{"summary":"Everything recorded for ozempic in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)","operationId":"api_v1_dossier_ozempic_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/eliquis.json":{"get":{"summary":"Everything recorded for eliquis in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)","operationId":"api_v1_dossier_eliquis_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/farxiga.json":{"get":{"summary":"Everything recorded for farxiga in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)","operationId":"api_v1_dossier_farxiga_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/jardiance.json":{"get":{"summary":"Everything recorded for jardiance in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)","operationId":"api_v1_dossier_jardiance_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/entresto.json":{"get":{"summary":"Everything recorded for entresto in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)","operationId":"api_v1_dossier_entresto_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/trulicity.json":{"get":{"summary":"Everything recorded for trulicity in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)","operationId":"api_v1_dossier_trulicity_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/cosentyx.json":{"get":{"summary":"Everything recorded for cosentyx in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)","operationId":"api_v1_dossier_cosentyx_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/janumet.json":{"get":{"summary":"Everything recorded for janumet in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)","operationId":"api_v1_dossier_janumet_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/biktarvy.json":{"get":{"summary":"Everything recorded for biktarvy in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)","operationId":"api_v1_dossier_biktarvy_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/xarelto.json":{"get":{"summary":"Everything recorded for xarelto in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)","operationId":"api_v1_dossier_xarelto_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/enbrel.json":{"get":{"summary":"Everything recorded for enbrel in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)","operationId":"api_v1_dossier_enbrel_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/trelegy-ellipta.json":{"get":{"summary":"Everything recorded for trelegy ellipta in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)","operationId":"api_v1_dossier_trelegy_ellipta_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/anoro-ellipta.json":{"get":{"summary":"Everything recorded for anoro ellipta in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)","operationId":"api_v1_dossier_anoro_ellipta_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/austedo.json":{"get":{"summary":"Everything recorded for austedo in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)","operationId":"api_v1_dossier_austedo_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/breo-ellipta.json":{"get":{"summary":"Everything recorded for breo ellipta in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)","operationId":"api_v1_dossier_breo_ellipta_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/calquence.json":{"get":{"summary":"Everything recorded for calquence in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)","operationId":"api_v1_dossier_calquence_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/cimzia.json":{"get":{"summary":"Everything recorded for cimzia in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)","operationId":"api_v1_dossier_cimzia_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/entyvio.json":{"get":{"summary":"Everything recorded for entyvio in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)","operationId":"api_v1_dossier_entyvio_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/erleada.json":{"get":{"summary":"Everything recorded for erleada in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)","operationId":"api_v1_dossier_erleada_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/ibrance.json":{"get":{"summary":"Everything recorded for ibrance in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)","operationId":"api_v1_dossier_ibrance_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/imbruvica.json":{"get":{"summary":"Everything recorded for imbruvica in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)","operationId":"api_v1_dossier_imbruvica_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/januvia.json":{"get":{"summary":"Everything recorded for januvia in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)","operationId":"api_v1_dossier_januvia_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/kisqali.json":{"get":{"summary":"Everything recorded for kisqali in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)","operationId":"api_v1_dossier_kisqali_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/lenvima.json":{"get":{"summary":"Everything recorded for lenvima in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)","operationId":"api_v1_dossier_lenvima_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/linzess.json":{"get":{"summary":"Everything recorded for linzess in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)","operationId":"api_v1_dossier_linzess_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/novolog.json":{"get":{"summary":"Everything recorded for novolog in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)","operationId":"api_v1_dossier_novolog_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/ofev.json":{"get":{"summary":"Everything recorded for ofev in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)","operationId":"api_v1_dossier_ofev_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/orencia.json":{"get":{"summary":"Everything recorded for orencia in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)","operationId":"api_v1_dossier_orencia_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/otezla.json":{"get":{"summary":"Everything recorded for otezla in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)","operationId":"api_v1_dossier_otezla_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/pomalyst.json":{"get":{"summary":"Everything recorded for pomalyst in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)","operationId":"api_v1_dossier_pomalyst_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/rexulti.json":{"get":{"summary":"Everything recorded for rexulti in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)","operationId":"api_v1_dossier_rexulti_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/stelara.json":{"get":{"summary":"Everything recorded for stelara in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)","operationId":"api_v1_dossier_stelara_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/tradjenta.json":{"get":{"summary":"Everything recorded for tradjenta in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)","operationId":"api_v1_dossier_tradjenta_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/verzenio.json":{"get":{"summary":"Everything recorded for verzenio in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)","operationId":"api_v1_dossier_verzenio_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/vraylar.json":{"get":{"summary":"Everything recorded for vraylar in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)","operationId":"api_v1_dossier_vraylar_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/xeljanz.json":{"get":{"summary":"Everything recorded for xeljanz in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)","operationId":"api_v1_dossier_xeljanz_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/xifaxan.json":{"get":{"summary":"Everything recorded for xifaxan in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)","operationId":"api_v1_dossier_xifaxan_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/xolair.json":{"get":{"summary":"Everything recorded for xolair in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)","operationId":"api_v1_dossier_xolair_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/xtandi.json":{"get":{"summary":"Everything recorded for xtandi in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)","operationId":"api_v1_dossier_xtandi_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/mounjaro.json":{"get":{"summary":"Everything recorded for Mounjaro in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_mounjaro_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/humira.json":{"get":{"summary":"Everything recorded for Humira in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_humira_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/revlimid.json":{"get":{"summary":"Everything recorded for Revlimid in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_revlimid_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/vyndamax.json":{"get":{"summary":"Everything recorded for Vyndamax in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_vyndamax_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/dupixent.json":{"get":{"summary":"Everything recorded for Dupixent in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_dupixent_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/skyrizi.json":{"get":{"summary":"Everything recorded for Skyrizi in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_skyrizi_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/myrbetriq.json":{"get":{"summary":"Everything recorded for Myrbetriq in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_myrbetriq_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/jakafi.json":{"get":{"summary":"Everything recorded for Jakafi in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_jakafi_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/ingrezza.json":{"get":{"summary":"Everything recorded for Ingrezza in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_ingrezza_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/repatha.json":{"get":{"summary":"Everything recorded for Repatha in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_repatha_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/invega-sustenna.json":{"get":{"summary":"Everything recorded for Invega Sustenna in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_invega_sustenna_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/tresiba.json":{"get":{"summary":"Everything recorded for Tresiba in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_tresiba_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/brukinsa.json":{"get":{"summary":"Everything recorded for Brukinsa in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_brukinsa_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/tagrisso.json":{"get":{"summary":"Everything recorded for Tagrisso in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_tagrisso_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/rinvoq.json":{"get":{"summary":"Everything recorded for Rinvoq in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_rinvoq_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/restasis.json":{"get":{"summary":"Everything recorded for Restasis in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_restasis_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/opsumit.json":{"get":{"summary":"Everything recorded for Opsumit in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_opsumit_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/cabometyx.json":{"get":{"summary":"Everything recorded for Cabometyx in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_cabometyx_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/toujeo.json":{"get":{"summary":"Everything recorded for Toujeo in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_toujeo_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/nubeqa.json":{"get":{"summary":"Everything recorded for Nubeqa in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_nubeqa_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/gemtesa.json":{"get":{"summary":"Everything recorded for Gemtesa in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_gemtesa_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/venclexta.json":{"get":{"summary":"Everything recorded for Venclexta in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_venclexta_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/uptravi.json":{"get":{"summary":"Everything recorded for Uptravi in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_uptravi_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/spiriva-respimat.json":{"get":{"summary":"Everything recorded for Spiriva Respimat in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_spiriva_respimat_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/lantus.json":{"get":{"summary":"Everything recorded for Lantus in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_lantus_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/prolia.json":{"get":{"summary":"Everything recorded for Prolia in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_prolia_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/tyvaso-dpi.json":{"get":{"summary":"Everything recorded for Tyvaso Dpi in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_tyvaso_dpi_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/vascepa.json":{"get":{"summary":"Everything recorded for Vascepa in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_vascepa_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/oxervate.json":{"get":{"summary":"Everything recorded for Oxervate in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_oxervate_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/adempas.json":{"get":{"summary":"Everything recorded for Adempas in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_adempas_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/brilinta.json":{"get":{"summary":"Everything recorded for Brilinta in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_brilinta_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/promacta.json":{"get":{"summary":"Everything recorded for Promacta in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_promacta_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/basaglar.json":{"get":{"summary":"Everything recorded for Basaglar in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_basaglar_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/humalog.json":{"get":{"summary":"Everything recorded for Humalog in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_humalog_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/nuplazid.json":{"get":{"summary":"Everything recorded for Nuplazid in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_nuplazid_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/lumigan.json":{"get":{"summary":"Everything recorded for Lumigan in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_lumigan_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/abilify-maintena.json":{"get":{"summary":"Everything recorded for Abilify Maintena in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_abilify_maintena_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/tivicay.json":{"get":{"summary":"Everything recorded for Tivicay in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_tivicay_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/nurtec-odt.json":{"get":{"summary":"Everything recorded for Nurtec ODT in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_nurtec_odt_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/tremfya.json":{"get":{"summary":"Everything recorded for Tremfya in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_tremfya_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/zenpep.json":{"get":{"summary":"Everything recorded for Zenpep in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_zenpep_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/lynparza.json":{"get":{"summary":"Everything recorded for Lynparza in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_lynparza_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/kesimpta.json":{"get":{"summary":"Everything recorded for Kesimpta in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_kesimpta_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/triumeq.json":{"get":{"summary":"Everything recorded for Triumeq in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_triumeq_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/taltz.json":{"get":{"summary":"Everything recorded for Taltz in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_taltz_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/albuterol-sulfate-hfa.json":{"get":{"summary":"Everything recorded for Albuterol Sulfate HFA in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_albuterol_sulfate_hfa_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/genvoya.json":{"get":{"summary":"Everything recorded for Genvoya in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_genvoya_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/invega-trinza.json":{"get":{"summary":"Everything recorded for Invega Trinza in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_invega_trinza_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/descovy.json":{"get":{"summary":"Everything recorded for Descovy in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_descovy_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/sprycel.json":{"get":{"summary":"Everything recorded for Sprycel in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_sprycel_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/xiidra.json":{"get":{"summary":"Everything recorded for Xiidra in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_xiidra_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/spiriva-handihaler.json":{"get":{"summary":"Everything recorded for Spiriva Handihaler in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_spiriva_handihaler_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/orgovyx.json":{"get":{"summary":"Everything recorded for Orgovyx in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_orgovyx_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/stiolto-respimat.json":{"get":{"summary":"Everything recorded for Stiolto Respimat in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_stiolto_respimat_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/inlyta.json":{"get":{"summary":"Everything recorded for Inlyta in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_inlyta_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/velphoro.json":{"get":{"summary":"Everything recorded for Velphoro in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_velphoro_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/ubrelvy.json":{"get":{"summary":"Everything recorded for Ubrelvy in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_ubrelvy_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/tasigna.json":{"get":{"summary":"Everything recorded for Tasigna in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_tasigna_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/multaq.json":{"get":{"summary":"Everything recorded for Multaq in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_multaq_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/kerendia.json":{"get":{"summary":"Everything recorded for Kerendia in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_kerendia_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/trintellix.json":{"get":{"summary":"Everything recorded for Trintellix in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_trintellix_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/combivent-respimat.json":{"get":{"summary":"Everything recorded for Combivent Respimat in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_combivent_respimat_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/incruse-ellipta.json":{"get":{"summary":"Everything recorded for Incruse Ellipta in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_incruse_ellipta_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/radicava-ors.json":{"get":{"summary":"Everything recorded for Radicava Ors in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_radicava_ors_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/odefsey.json":{"get":{"summary":"Everything recorded for Odefsey in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_odefsey_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/actemra.json":{"get":{"summary":"Everything recorded for Actemra in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_actemra_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/acthar.json":{"get":{"summary":"Everything recorded for Acthar in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_acthar_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/gattex.json":{"get":{"summary":"Everything recorded for Gattex in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_gattex_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/synthroid.json":{"get":{"summary":"Everything recorded for Synthroid in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_synthroid_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/strensiq.json":{"get":{"summary":"Everything recorded for Strensiq in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_strensiq_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/korlym.json":{"get":{"summary":"Everything recorded for Korlym in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_korlym_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/ojjaara.json":{"get":{"summary":"Everything recorded for Ojjaara in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_ojjaara_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/praluent.json":{"get":{"summary":"Everything recorded for Praluent in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_praluent_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/synjardy-xr.json":{"get":{"summary":"Everything recorded for Synjardy XR in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_synjardy_xr_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/advair-hfa.json":{"get":{"summary":"Everything recorded for Advair HFA in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_advair_hfa_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/nucala.json":{"get":{"summary":"Everything recorded for Nucala in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_nucala_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/aimovig.json":{"get":{"summary":"Everything recorded for Aimovig in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_aimovig_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/soliqua.json":{"get":{"summary":"Everything recorded for Soliqua in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_soliqua_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/camzyos.json":{"get":{"summary":"Everything recorded for Camzyos in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_camzyos_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/avonex.json":{"get":{"summary":"Everything recorded for Avonex in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_avonex_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/ninlaro.json":{"get":{"summary":"Everything recorded for Ninlaro in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_ninlaro_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/invokana.json":{"get":{"summary":"Everything recorded for Invokana in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_invokana_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/aristada.json":{"get":{"summary":"Everything recorded for Aristada in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_aristada_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/caplyta.json":{"get":{"summary":"Everything recorded for Caplyta in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_caplyta_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/forteo.json":{"get":{"summary":"Everything recorded for Forteo in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_forteo_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/tibsovo.json":{"get":{"summary":"Everything recorded for Tibsovo in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_tibsovo_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/qulipta.json":{"get":{"summary":"Everything recorded for Qulipta in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_qulipta_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/orserdu.json":{"get":{"summary":"Everything recorded for Orserdu in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_orserdu_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/emgality.json":{"get":{"summary":"Everything recorded for Emgality in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_emgality_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/tymlos.json":{"get":{"summary":"Everything recorded for Tymlos in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_tymlos_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/copaxone.json":{"get":{"summary":"Everything recorded for Copaxone in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_copaxone_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/premarin.json":{"get":{"summary":"Everything recorded for Premarin in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_premarin_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/rezurock.json":{"get":{"summary":"Everything recorded for Rezurock in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_rezurock_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/vyvgart.json":{"get":{"summary":"Everything recorded for Vyvgart in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_vyvgart_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/humulin-r.json":{"get":{"summary":"Everything recorded for Humulin R in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_humulin_r_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/lokelma.json":{"get":{"summary":"Everything recorded for Lokelma in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_lokelma_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/bosulif.json":{"get":{"summary":"Everything recorded for Bosulif in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_bosulif_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/ultomiris.json":{"get":{"summary":"Everything recorded for Ultomiris in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_ultomiris_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/xtampza-er.json":{"get":{"summary":"Everything recorded for Xtampza ER in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_xtampza_er_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/fasenra.json":{"get":{"summary":"Everything recorded for Fasenra in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_fasenra_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/zejula.json":{"get":{"summary":"Everything recorded for Zejula in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_zejula_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/takhzyro.json":{"get":{"summary":"Everything recorded for Takhzyro in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_takhzyro_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/briviact.json":{"get":{"summary":"Everything recorded for Briviact in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_briviact_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/benlysta.json":{"get":{"summary":"Everything recorded for Benlysta in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_benlysta_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/teriparatide.json":{"get":{"summary":"Everything recorded for Teriparatide in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_teriparatide_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/krystexxa.json":{"get":{"summary":"Everything recorded for Krystexxa in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_krystexxa_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/cabenuva.json":{"get":{"summary":"Everything recorded for Cabenuva in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_cabenuva_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/epidiolex.json":{"get":{"summary":"Everything recorded for Epidiolex in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_epidiolex_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/mekinist.json":{"get":{"summary":"Everything recorded for Mekinist in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_mekinist_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/welireg.json":{"get":{"summary":"Everything recorded for Welireg in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_welireg_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/xigduo-xr.json":{"get":{"summary":"Everything recorded for Xigduo XR in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_xigduo_xr_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/victoza-3-pak.json":{"get":{"summary":"Everything recorded for Victoza 3-Pak in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_victoza_3_pak_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/jaypirca.json":{"get":{"summary":"Everything recorded for Jaypirca in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_jaypirca_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/arnuity-ellipta.json":{"get":{"summary":"Everything recorded for Arnuity Ellipta in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_arnuity_ellipta_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/scemblix.json":{"get":{"summary":"Everything recorded for Scemblix in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_scemblix_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/wixela-inhub.json":{"get":{"summary":"Everything recorded for Wixela Inhub in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_wixela_inhub_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/soliris.json":{"get":{"summary":"Everything recorded for Soliris in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_soliris_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/ocrevus.json":{"get":{"summary":"Everything recorded for Ocrevus in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_ocrevus_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/vumerity.json":{"get":{"summary":"Everything recorded for Vumerity in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_vumerity_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/metformin-hcl.json":{"get":{"summary":"Everything recorded for Metformin HCl in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_metformin_hcl_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/arikayce.json":{"get":{"summary":"Everything recorded for Arikayce in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_arikayce_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/simponi.json":{"get":{"summary":"Everything recorded for Simponi in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_simponi_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/truqap.json":{"get":{"summary":"Everything recorded for Truqap in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_truqap_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/tezspire.json":{"get":{"summary":"Everything recorded for Tezspire in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_tezspire_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/synjardy.json":{"get":{"summary":"Everything recorded for Synjardy in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_synjardy_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/mavenclad.json":{"get":{"summary":"Everything recorded for Mavenclad in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_mavenclad_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/winrevair.json":{"get":{"summary":"Everything recorded for Winrevair in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_winrevair_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/tafinlar.json":{"get":{"summary":"Everything recorded for Tafinlar in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_tafinlar_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/kevzara.json":{"get":{"summary":"Everything recorded for Kevzara in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_kevzara_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/rhopressa.json":{"get":{"summary":"Everything recorded for Rhopressa in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_rhopressa_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/trazodone-hcl.json":{"get":{"summary":"Everything recorded for Trazodone HCl in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_trazodone_hcl_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/xcopri.json":{"get":{"summary":"Everything recorded for Xcopri in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_xcopri_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/lupron-depot.json":{"get":{"summary":"Everything recorded for Lupron Depot in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_lupron_depot_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/tecfidera.json":{"get":{"summary":"Everything recorded for Tecfidera in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_tecfidera_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/combigan.json":{"get":{"summary":"Everything recorded for Combigan in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_combigan_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/dulera.json":{"get":{"summary":"Everything recorded for Dulera in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_dulera_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/belbuca.json":{"get":{"summary":"Everything recorded for Belbuca in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_belbuca_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/ayvakit.json":{"get":{"summary":"Everything recorded for Ayvakit in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_ayvakit_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/prednisolone-acetate.json":{"get":{"summary":"Everything recorded for Prednisolone Acetate in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_prednisolone_acetate_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/evrysdi.json":{"get":{"summary":"Everything recorded for Evrysdi in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_evrysdi_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/insulin-lispro.json":{"get":{"summary":"Everything recorded for Insulin Lispro in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_insulin_lispro_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/dificid.json":{"get":{"summary":"Everything recorded for Dificid in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_dificid_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/lumakras.json":{"get":{"summary":"Everything recorded for Lumakras in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_lumakras_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/ventolin-hfa.json":{"get":{"summary":"Everything recorded for Ventolin HFA in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_ventolin_hfa_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/tepezza.json":{"get":{"summary":"Everything recorded for Tepezza in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_tepezza_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/belsomra.json":{"get":{"summary":"Everything recorded for Belsomra in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_belsomra_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/aubagio.json":{"get":{"summary":"Everything recorded for Aubagio in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_aubagio_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/sertraline-hcl.json":{"get":{"summary":"Everything recorded for Sertraline HCl in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_sertraline_hcl_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/glyxambi.json":{"get":{"summary":"Everything recorded for Glyxambi in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_glyxambi_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/amvuttra.json":{"get":{"summary":"Everything recorded for Amvuttra in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_amvuttra_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/keytruda.json":{"get":{"summary":"Everything recorded for Keytruda in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_keytruda_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/tukysa.json":{"get":{"summary":"Everything recorded for Tukysa in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_tukysa_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/braftovi.json":{"get":{"summary":"Everything recorded for Braftovi in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_braftovi_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/fruzaqla.json":{"get":{"summary":"Everything recorded for Fruzaqla in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_fruzaqla_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/relistor.json":{"get":{"summary":"Everything recorded for Relistor in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_relistor_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/varenicline-tartrate.json":{"get":{"summary":"Everything recorded for Varenicline Tartrate in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_varenicline_tartrate_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/wakix.json":{"get":{"summary":"Everything recorded for Wakix in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_wakix_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/auryxia.json":{"get":{"summary":"Everything recorded for Auryxia in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_auryxia_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/vyzulta.json":{"get":{"summary":"Everything recorded for Vyzulta in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_vyzulta_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/lybalvi.json":{"get":{"summary":"Everything recorded for Lybalvi in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_lybalvi_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/simvastatin.json":{"get":{"summary":"Everything recorded for Simvastatin in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_simvastatin_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/vyvgart-hytrulo.json":{"get":{"summary":"Everything recorded for Vyvgart Hytrulo in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_vyvgart_hytrulo_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/tabrecta.json":{"get":{"summary":"Everything recorded for Tabrecta in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_tabrecta_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/trulance.json":{"get":{"summary":"Everything recorded for Trulance in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_trulance_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/pradaxa.json":{"get":{"summary":"Everything recorded for Pradaxa in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_pradaxa_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/cresemba.json":{"get":{"summary":"Everything recorded for Cresemba in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_cresemba_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/omeprazole-sodium-bicarbonate.json":{"get":{"summary":"Everything recorded for Omeprazole-Sodium Bicarbonate in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_omeprazole_sodium_bicarbonate_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/botox.json":{"get":{"summary":"Everything recorded for Botox in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_botox_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/xphozah.json":{"get":{"summary":"Everything recorded for Xphozah in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_xphozah_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/levemir.json":{"get":{"summary":"Everything recorded for Levemir in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_levemir_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/prevymis.json":{"get":{"summary":"Everything recorded for Prevymis in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_prevymis_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/fotivda.json":{"get":{"summary":"Everything recorded for Fotivda in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_fotivda_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/remicade.json":{"get":{"summary":"Everything recorded for Remicade in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_remicade_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/jublia.json":{"get":{"summary":"Everything recorded for Jublia in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_jublia_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/venlafaxine-hcl-er.json":{"get":{"summary":"Everything recorded for Venlafaxine HCl ER in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_venlafaxine_hcl_er_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/erivedge.json":{"get":{"summary":"Everything recorded for Erivedge in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_erivedge_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/lorbrena.json":{"get":{"summary":"Everything recorded for Lorbrena in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_lorbrena_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/miebo.json":{"get":{"summary":"Everything recorded for Miebo in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_miebo_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/atrovent-hfa.json":{"get":{"summary":"Everything recorded for Atrovent HFA in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_atrovent_hfa_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/risperdal-consta.json":{"get":{"summary":"Everything recorded for Risperdal Consta in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_risperdal_consta_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/isentress.json":{"get":{"summary":"Everything recorded for Isentress in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_isentress_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/diclofenac-epolamine.json":{"get":{"summary":"Everything recorded for Diclofenac Epolamine in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_diclofenac_epolamine_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/buspirone-hcl.json":{"get":{"summary":"Everything recorded for Buspirone HCl in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_buspirone_hcl_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/vonjo.json":{"get":{"summary":"Everything recorded for Vonjo in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_vonjo_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/piqray.json":{"get":{"summary":"Everything recorded for Piqray in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_piqray_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/serostim.json":{"get":{"summary":"Everything recorded for Serostim in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_serostim_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/invega-hafyera.json":{"get":{"summary":"Everything recorded for Invega Hafyera in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_invega_hafyera_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/sucraid.json":{"get":{"summary":"Everything recorded for Sucraid in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_sucraid_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/valacyclovir.json":{"get":{"summary":"Everything recorded for Valacyclovir in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_valacyclovir_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/nuzyra.json":{"get":{"summary":"Everything recorded for Nuzyra in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_nuzyra_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/xospata.json":{"get":{"summary":"Everything recorded for Xospata in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_xospata_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/opzelura.json":{"get":{"summary":"Everything recorded for Opzelura in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_opzelura_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/rebif.json":{"get":{"summary":"Everything recorded for Rebif in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_rebif_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/jynarque.json":{"get":{"summary":"Everything recorded for Jynarque in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_jynarque_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/darzalex-faspro.json":{"get":{"summary":"Everything recorded for Darzalex Faspro in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_darzalex_faspro_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/skyclarys.json":{"get":{"summary":"Everything recorded for Skyclarys in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_skyclarys_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/gocovri.json":{"get":{"summary":"Everything recorded for Gocovri in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_gocovri_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/trijardy-xr.json":{"get":{"summary":"Everything recorded for Trijardy XR in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_trijardy_xr_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/nifedipine-er.json":{"get":{"summary":"Everything recorded for Nifedipine ER in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_nifedipine_er_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/xpovio.json":{"get":{"summary":"Everything recorded for Xpovio in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_xpovio_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/stivarga.json":{"get":{"summary":"Everything recorded for Stivarga in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_stivarga_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/mektovi.json":{"get":{"summary":"Everything recorded for Mektovi in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_mektovi_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/evenity.json":{"get":{"summary":"Everything recorded for Evenity in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_evenity_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/fentanyl.json":{"get":{"summary":"Everything recorded for Fentanyl in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_fentanyl_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/dossier/betaseron.json":{"get":{"summary":"Everything recorded for Betaseron in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)","operationId":"api_v1_dossier_betaseron_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/findings/brand_vs_authorized_generic.json":{"get":{"summary":"Medicare negotiated price per unit against the pharmacy cost of an authorized generic of the same drug, with its recompute recipe","operationId":"api_v1_findings_brand_vs_authorized_generic_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/findings/ful_survey_share.json":{"get":{"summary":"Share of federal upper limits set by the pharmacy survey price, by period, with its recompute recipe","operationId":"api_v1_findings_ful_survey_share_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/changes/last-30-days.json":{"get":{"summary":"Change events recorded since 2026-10-12 (shortage rows, program status, NADAC prices); regenerated with each build","operationId":"api_v1_changes_last_30_days_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/termination/calendar.json":{"get":{"summary":"Every package with a termination date after today (newest CMS quarter)","operationId":"api_v1_termination_calendar_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/states/insulin-caps.json":{"get":{"summary":"State insulin copay caps: one row per state we read, with the cap, its period, plan types, the quoted statute sentence, source URL, read date and fact id; a state not listed is unread, not lawless (state_facts envelope)","operationId":"api_v1_states_insulin_caps_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/states/spap.json":{"get":{"summary":"State pharmaceutical assistance programs on the CMS best-price exclusion list: states, program names and counts; says nothing about eligibility or current operation (state_facts envelope)","operationId":"api_v1_states_spap_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/states/index.json":{"get":{"summary":"Index of the state-level files and the states each one lists (state_facts envelope)","operationId":"api_v1_states_index_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/Envelope"}}}}}}},"/api/v1/assistance/pack.json":{"get":{"summary":"Assistance programs, medicines, poverty table, and each program's dated status and ceiling proof (inputs of the matcher)","operationId":"api_v1_assistance_pack_json","responses":{"200":{"description":"OK","content":{"application/json":{}}}}}},"/api/v1/assistance/matcher.mjs":{"get":{"summary":"The finder's matching logic as an ES module (findPrograms, incomeCeilingFor, matchDrug, incomeStatus); run it locally on the pack","operationId":"api_v1_assistance_matcher_mjs","responses":{"200":{"description":"OK","content":{"text/javascript":{}}}}}},"/api/v1/index.json":{"get":{"summary":"Index of routes, the edition and how to verify it","operationId":"index","responses":{"200":{"description":"OK"}}}},"/conditions/index.json":{"get":{"summary":"Every condition hub with its fund counts, link and JSON twin","operationId":"conditions_index_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/ConditionIndex"}}}}}}},"/conditions/ladders.json":{"get":{"summary":"Every route ladder (condition x drug) with its page and JSON twin: the way to enumerate /conditions/{condition}/{ingredient}.json","operationId":"conditions_ladders_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/LadderIndex"}}}}}}},"/conditions/{condition}.json":{"get":{"summary":"One condition hub as data: the charitable funds we hold for it and the drugs whose FDA label names it","operationId":"conditions_condition_json","parameters":[{"name":"condition","in":"path","required":true,"description":"a condition id from /conditions/index.json","schema":{"type":"string","pattern":"^[a-z0-9-]+$"}}],"responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/ConditionHub"}}}},"404":{"description":"No such file: only listed values exist"}}}},"/conditions/{condition}/{ingredient}.json":{"get":{"summary":"The six routes to paying for one drug for one condition, in a fixed order that is not a ranking, each with its source, read date and receipt","operationId":"conditions_condition_ingredient_json","parameters":[{"name":"condition","in":"path","required":true,"description":"a condition id","schema":{"type":"string","pattern":"^[a-z0-9-]+$"}},{"name":"ingredient","in":"path","required":true,"description":"an ingredient slug","schema":{"type":"string","pattern":"^[a-z0-9-]+$"}}],"responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/RouteLadder"}}}},"404":{"description":"No such file: only listed values exist"}}}},"/fact/{id}.json":{"get":{"summary":"One recorded fact as stored: value, source, read date, licence label, verifying quote, edition root, and hashes of the exact stored text. Ids are the fact_id values in dossier receipts and ladder twins; not every fact in the edition has a page","operationId":"fact_id_json","parameters":[{"name":"id","in":"path","required":true,"description":"a fact_id (24 hex characters)","schema":{"type":"string","pattern":"^[0-9a-f]{24}$"}}],"responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/FactTwin"}}}},"404":{"description":"No such file: only listed values exist"}}}},"/assistance/funds.json":{"get":{"summary":"Every charitable copay fund we hold with its status, the date the page gave and the date we read it","operationId":"assistance_funds_json","responses":{"200":{"description":"OK","content":{"application/json":{"schema":{"$ref":"#/components/schemas/FundBoard"}}}}}}}},"components":{"schemas":{"Envelope":{"type":"object","required":["answer","receipts","as_of","edition","licence","unknown","disclaimer"],"properties":{"answer":{"description":"The result, or null when the edition holds no answer (see unknown)."},"receipts":{"type":"array","items":{"type":"object","required":["fact_id","field","entity"],"properties":{"fact_id":{"type":"string"},"field":{"type":"string"},"entity":{"type":"string"}}}},"as_of":{"type":"object","properties":{"newest_fact_retrieved_at":{"type":["string","null"]}}},"edition":{"type":"object","properties":{"id":{"type":["string","null"]},"merkleRoot":{"type":["string","null"]},"factCount":{"type":"integer"},"manifestPresent":{"type":"boolean"}}},"licence":{"type":"object","properties":{"classes":{"type":"array","items":{"type":"string"}},"note":{"type":"string"}}},"unknown":{"type":"array","description":"What the edition cannot say. Never fill these gaps from memory.","items":{"type":"object","required":["code","field","reason"],"properties":{"code":{"enum":["NO_DATA","STALE_PERIOD","NOT_PROVIDED","OUT_OF_SCOPE_CLINICAL","AMBIGUOUS"]},"field":{"type":"string"},"reason":{"type":"string"}}}},"disclaimer":{"type":"string"}}},"LadderProgram":{"type":"object","required":["name","url","programPageIsExternal","inCurrentList"],"properties":{"name":{"type":"string"},"url":{"type":"string","pattern":"^https?://"},"programPageIsExternal":{"type":"boolean"},"inCurrentList":{"type":"boolean","description":"false when the program's page printed this drug in an earlier list and not in its current one"},"note":{"type":["string","null"]},"listKind":{"type":["string","null"]},"status":{"type":["string","null"]},"statusRead":{"type":["string","null"]},"fact_id":{"type":["string","null"],"pattern":"^[0-9a-f]{24}$","description":"receipt: resolves at /fact/<id>.json when present"}}},"LadderRoute":{"type":"object","required":["id","title","found"],"properties":{"id":{"enum":["label","part-d","price","program","funds","trials"]},"title":{"type":"string"},"found":{"type":"boolean"},"source":{"type":["string","null"]},"readOn":{"type":["string","null"]},"fact_id":{"type":["string","null"],"pattern":"^[0-9a-f]{24}$"},"quote":{"type":"string"},"context":{"type":"string"},"text":{"type":["string","null"]},"usd30DaySupply":{"type":["number","null"]},"effective":{"type":["string","null"]},"recruitingInterventionalTrials":{"type":["integer","null"]},"programs":{"type":"array","items":{"$ref":"#/components/schemas/LadderProgram"}},"fundsHeld":{"type":"integer"},"open":{"type":"integer"},"openFunds":{"type":"array"},"hubUrl":{"type":"string"}}},"RouteLadder":{"type":"object","required":["page","edition","editionRoot","license","generated","condition","drug","orderIsRanking","orderNote","routes"],"properties":{"page":{"type":"string","pattern":"^https://omnirx\\.org/conditions/[a-z0-9-]+/[a-z0-9-]+$"},"edition":{"type":"string"},"editionRoot":{"type":"string"},"license":{"type":"string"},"generated":{"type":"string"},"condition":{"type":"object","required":["id","name"],"properties":{"id":{"type":"string"},"name":{"type":"string"}}},"drug":{"type":"object","required":["ingredient","brands"],"properties":{"ingredient":{"type":"string"},"brands":{"type":"array","items":{"type":"string"}}}},"orderIsRanking":{"enum":[false],"description":"always false: the order is fixed, never a ranking"},"orderNote":{"type":"string"},"routes":{"type":"array","minItems":6,"maxItems":6,"items":{"$ref":"#/components/schemas/LadderRoute"},"description":"the six routes in this fixed order: label, part-d, price, program, funds, trials"}}},"FactTwin":{"type":"object","required":["page","fact_id","edition","editionRoot","license","entity_type","entity_key","field","value_sha256","source_url","retrieved_at","method","verify","licence_status","licence_label"],"properties":{"page":{"type":"string","pattern":"^https://omnirx\\.org/fact/[0-9a-f]{24}$"},"fact_id":{"type":"string","pattern":"^[0-9a-f]{24}$"},"edition":{"type":"string"},"editionRoot":{"type":"string"},"license":{"type":"string"},"entity_type":{"type":"string"},"entity_key":{"type":"string"},"field":{"type":"string"},"value":{"description":"the value as stored, parsed; null when it was not JSON"},"value_sha256":{"type":"string","pattern":"^[0-9a-f]{64}$","description":"sha256 of the exact stored value text"},"source_url":{"type":"string"},"retrieved_at":{"type":"string"},"source_version":{"type":["string","null"]},"method":{"type":"string"},"verify":{"type":"string"},"licence_status":{"type":"string"},"licence_label":{"type":"string"},"quote":{"type":["string","null"]},"quote_sha256":{"type":["string","null"],"pattern":"^[0-9a-f]{64}$","description":"sha256 of the exact stored quote text; null when the fact carries no quote"}}},"ConditionIndex":{"type":"object","required":["edition","merkleRoot","readOn","counts","conditions","licence"],"properties":{"edition":{"type":"string"},"merkleRoot":{"type":"string"},"readOn":{"type":"string"},"counts":{"type":"object"},"licence":{"type":"string"},"conditions":{"type":"array","items":{"type":"object","required":["id","name","bodySystem","url","json"],"properties":{"id":{"type":"string"},"name":{"type":"string"},"bodySystem":{"type":"string"},"url":{"type":"string"},"json":{"type":"string"},"funds":{"type":"integer"},"open":{"type":"integer"},"closed":{"type":"integer"}}}}}},"LadderIndex":{"type":"object","required":["edition","merkleRoot","count","ladders","licence"],"properties":{"edition":{"type":"string"},"merkleRoot":{"type":"string"},"count":{"type":"integer"},"licence":{"type":"string"},"note":{"type":"string"},"ladders":{"type":"array","items":{"type":"object","required":["condition","ingredient","brands","page","json"],"properties":{"condition":{"type":"object","required":["id","name"],"properties":{"id":{"type":"string"},"name":{"type":"string"}}},"ingredient":{"type":"string"},"brands":{"type":"array","items":{"type":"string"}},"page":{"type":"string"},"json":{"type":"string"}}}}}},"ConditionHub":{"type":"object","required":["id","name","bodySystem","edition","merkleRoot","counts","funds","drugsWhoseLabelNamesThisCondition","licence"],"properties":{"id":{"type":"string"},"name":{"type":"string"},"bodySystem":{"type":"string"},"edition":{"type":"string"},"merkleRoot":{"type":"string"},"licence":{"type":"string"},"counts":{"type":"object"},"funds":{"type":"array","items":{"type":"object","required":["fund","organization","status","readOn","source"],"properties":{"fund":{"type":"string"},"organization":{"type":"string"},"status":{"enum":["open","closed","limited","waitlist"]},"readOn":{"type":"string"},"source":{"type":"string"}}}},"drugsWhoseLabelNamesThisCondition":{"type":"array","items":{"type":"object","required":["ingredient","labelSentence","labelSource","manufacturerPrograms"],"properties":{"ingredient":{"type":"string"},"labelSentence":{"type":"string"},"labelSource":{"type":"string"},"manufacturerPrograms":{"type":"array","items":{"$ref":"#/components/schemas/LadderProgram"}}}}}}},"FundBoard":{"type":"object","required":["edition","merkleRoot","builtFrom","licence","note","rows"],"properties":{"edition":{"type":"string"},"merkleRoot":{"type":"string"},"builtFrom":{"type":"string"},"licence":{"type":"string"},"note":{"type":"string"},"rows":{"type":"array","items":{"type":"object","required":["program","organization","entity","status","readOn","source"],"properties":{"program":{"type":"string"},"organization":{"type":"string"},"entity":{"type":"string"},"status":{"enum":["open","closed","limited","waitlist"]},"dateOnPage":{"type":["string","null"]},"appliesTo":{"type":["string","null"]},"readOn":{"type":"string"},"source":{"type":"string"}}}}}}}}}